Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 01/19 10:38:30 am
1627.25 GBX   +3.68%
01/12European ADRs Move Higher in Tuesday Trading
MT
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
AQ
01/11European ADRs Move Sharply Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Arthrex: Who Are You Calling Inferior?

11/13/2020 | 09:13am EST

On October 13, the US Supreme Court granted certiorari in Arthrex v Smith & Nephew, (case numbers 19-1434, -1452, and -1458). Accordingly, the Supreme Court will now consider whether the Patent Trial and Appeal Board's (PTAB's) administrative patent judges (APJs) were unconstitutionally appointed.  

What Does the Case Concern?

The US Constitution requires that "Officers of the United States" be appointed by the President "with the advice and consent of the Senate". An exception is made for "inferior officers", which may be appointed without senate oversight and by either the President, courts of law, or heads of departments, as chosen by Congress.

Therefore, the constitutionally correct procedure for installing a federal officer depends on whether the officer is an "inferior" (in which case they may be appointed by a party chosen by Congress) or whether the officer is what courts have come to call a "principal" (in which case they must be appointed by the President with the Senate's advice and consent).

In this article, Finnegan attorneys Jason Romrell, Derek McCorquindale, and Brandon Andersen discuss Arthrex v Smith & Nephew and how the Supreme Court's decision may impact pending cases.

Read the full article here.

Originally published by World Intellectual Property Review.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Jason Romrell
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
901 New York Avenue, NW
Washington, DC
20001-4413
UNITED STATES
Tel: 2024084000
Fax: 2024084400
E-mail: info@finnegan.com
URL: www.finnegan.com

© Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about SMITH & NEPHEW PLC
01/12European ADRs Move Higher in Tuesday Trading
MT
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
AQ
01/11European ADRs Move Sharply Lower in Monday Trading
MT
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
DJ
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
MT
01/05SMITH & NEPHEW : Arthrex's Initial Merits Brief – Making The Case For Pate..
AQ
01/04SMITH & NEPHEW : Completes $240 Million Acquisition of Integra LifeSciences' Ext..
MT
01/04Smith & Nephew Plc Smith+Nephew Completes Orthopaedics Acquisition
DJ
01/04SMITH & NEPHEW : +Nephew completes Extremity Orthopaedics acquisition
PU
01/04SMITH & NEPHEW PLC : Acquisition
CO
More news
Financials (USD)
Sales 2020 4 590 M - -
Net income 2020 377 M - -
Net Debt 2020 1 638 M - -
P/E ratio 2020 52,2x
Yield 2020 1,33%
Capitalization 18 657 M 18 648 M -
EV / Sales 2020 4,42x
EV / Sales 2021 3,73x
Nbr of Employees 17 500
Free-Float 98,7%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 23,32 $
Last Close Price 21,32 $
Spread / Highest target 26,2%
Spread / Average Target 9,39%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors